TAG Chairman and Co-Founder, The Hon. Dr. Kurt Campbell Shares Thoughts on U.S.-China Relations in Interview with Bloomberg
“The steps that Treasury Secretary Bessent has taken, with his [Chinese] counterpart, the Vice Premier, at least appear to be ...
Media
Commentary
TAG Paper: Observations on Drug Pricing and Innovation in Japan
Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG
Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN
Key Findings
As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing policies that will support Japanese patients’ access to the most innovative medicines.
The Asia Group (TAG) has identified two specific pharmaceutical pricing measures that directly undermine the government’s goal of promoting startups and bringing innovative new pharmaceutical products to market. The negative impact of these policies is particularly severe for innovative drugs for rare diseases, for which there are often no alternative treatments:
The intended purpose of these rules is to improve transparency in a product’s total cost and provide incentives for drug launches in Japan. But the two-fold impact of these rules, particularly penalizing new market entrants and foreign entrants, has undermined the intended effect of these measures.
Eliminating these two specific punitive pricing policies represents “low-hanging fruit” for policy change, which can have an immediate impact on the availability of novel drugs, while having a relatively low impact on Japan’s healthcare budget. These changes will stimulate future successful launches and early entrance to Japan, benefitting patients.
Listen on:
Related Posts
TAG China Country Director, Han Lin, Comments in the Financial Times About the Significance of China Hosting the World Economic Forum “Summer Davos”
TAG China Country Director Han Lin Speaks at the World Economic Forum “Summer Davos” Held in Tianjin, China
TAG Chairman and Co-Founder, The Hon. Dr. Kurt Campbell Shares Thoughts on U.S.-China Relations in Interview with Bloomberg
TAG Partner Amb. Dan Kritenbrink Participates in Panel on U.S.-Vietnam Relations